OPRX
OptimizeRx CorporationNASDAQHealthcare$6.56+3.66%ClosedMarket Cap: $123.1M
As of 2026-04-06
Valuation
P/E (TTM)
23.98
PEG
0.19
P/B
0.99
P/S
1.17
EV/EBITDA
7.95
DCF Value
$-13.31
FCF Yield
14.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
63.3%
Operating Margin
11.0%
Net Margin
4.7%
ROE
4.2%
ROA
2.9%
ROIC
5.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $32.2M | 61.3% | $8.9M | $5.0M | $0.26 | — |
| FY 2025 | $109.4M | 63.3% | $12.1M | $5.1M | $0.27 | — |
| Q3 2025 | $26.1M | 67.2% | $2.0M | $779.0K | $0.04 | — |
| Q2 2025 | $29.2M | 63.8% | $3.2M | $1.5M | $0.08 | — |
| Q1 2025 | $21.9M | 60.9% | $-2.1M | $-2.2M | $-0.12 | — |
| Q4 2024 | $32.3M | 68.1% | $3.6M | $-78.0K | $-0.00 | — |
| FY 2024 | $92.1M | 64.5% | $-13.7M | $-20.1M | $-1.10 | — |
| Q3 2024 | $21.3M | 63.1% | $-8.6M | $-9.1M | $-0.50 | — |
| Q2 2024 | $18.8M | 62.2% | $-3.7M | $-4.0M | $-0.22 | — |
| Q1 2024 | $19.7M | 62.0% | $-5.0M | $-6.9M | $-0.38 | — |
| Q4 2023 | $28.4M | 62.9% | $-10.9M | $-4.1M | $-0.23 | — |
| FY 2023 | $71.5M | 60.0% | $-26.4M | $-17.6M | $-1.03 | — |